Company Overview
Snapshot
Founded in September 2010 by Ze'ev Harel, Dr. Aharon Bar-David, Avigail Keller, and Zeev Burshtein, Convergent R.N.R. operates with 11–50 employees. The company has raised $3.7 million across two funding rounds, with the Office of the Chief Scientist participating. In June 2017, Convergent R.N.R. established a collaboration with The University of Texas MD Anderson Cancer Center to further develop its radiation technology.
Business overview
Convergent R.N.R. is a medical technology startup focused on enhancing cancer treatment through its patented X-ray focusing technology, MercyBeam. This core product utilizes a lens to converge standard imaging X-rays into a precise treatment volume, aiming to increase therapeutic dosage at tumor locations while minimizing exposure to healthy tissues. The technology also removes low-energy photons that could harm the patient's skin and allows for the use of lower-energy X-rays compared to traditional linear accelerators. Convergent R.N.R. serves the healthcare industry, specifically targeting medical treatment and therapeutics, and operates within the Health Tech & Life Sciences sector.
Strategic signal
In June 2017, Convergent R.N.R. announced a significant collaboration with The University of Texas MD Anderson Cancer Center to advance its MercyBeam radiation technology. This partnership is crucial for the company as it provides a pathway for preclinical and clinical trials, aiming to establish MercyBeam as a leading solution for treating small tumors. For investors, this collaboration signals strong validation of Convergent R.N.R.'s technology and a clear trajectory towards clinical implementation and market leadership in radiation oncology.
Log in to access full profile ›Company Intelligence Q&A
- What is Convergent R.N.R.'s primary technology?
- Convergent R.N.R. develops MercyBeam, a patented X-ray focusing technology that uses a lens to converge standard imaging X-rays into a precise treatment volume for cancer therapy, aiming to spare healthy organs and cells.
- When was Convergent R.N.R. founded?
- Convergent R.N.R. was founded in September 2010.
- Which institution collaborated with Convergent R.N.R. to develop its radiation technology?
- In June 2017, The University of Texas MD Anderson Cancer Center established an alliance with Convergent R.N.R. to further develop its radiation technology, MercyBeam, with a focus on reducing side effects.
- Which investor participated in Convergent R.N.R.'s funding rounds?
- The Office of the Chief Scientist participated in Convergent R.N.R.'s funding rounds, including a $700,000 grant in July 2014 to build a prototype of their MercyBeam technology.
- What is the primary benefit of Convergent R.N.R.'s MercyBeam technology?
- MercyBeam increases the therapeutic dose delivered at the tumor location while significantly reducing the dose to surrounding healthy organs and cells, making radiotherapy treatment more accurate and safer.